LEIDEN, Netherlands, April 19,
2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming")
(Euronext Amsterdam: PHARM) (Nasdaq: PHAR) confirms it will
announce first quarter 2023 financial results for the month ended
March 31, 2023 on Thursday, May 11, 2023.
Pharming will host a presentation for analysts and investors at
13:30 CET/08:30 ET on May 11,
2023.
Dial in details for the presentation are detailed below.
Webcast Link:
https://webcast.openbriefing.com/pharming1q23/
Conference Call Dial-in Details:
Netherlands: +31 85 888 7233
United Kingdom (Local): +44 20
3936 2999
United Kingdom (Toll-Free): +44
808 189 0158
United States (Local): +1 646 664
1960
United States (Toll-Free): +1 855
979 6654
Global Dial-In Numbers
Access Code: 598957
About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is
a global biopharmaceutical company dedicated to transforming the
lives of patients with rare, debilitating, and life-threatening
diseases. Pharming is commercializing and developing an innovative
portfolio of protein replacement therapies and precision medicines,
including small molecules, biologics, and gene therapies that are
in early to late-stage development. Pharming is headquartered in
Leiden, Netherlands, and has
employees around the globe who serve patients in over 30 markets in
North America, Europe, the Middle
East, Africa, and
Asia-Pacific.
For more information, visit www.pharming.com and find us on
LinkedIn.
For further public information, contact:
Pharming Group, Leiden, The
Netherlands
Michael Levitan, VP Investor Relations & Corporate
Communications
T: +1 (908) 705 1696
Heather Robertson, Investor
Relations & Corporate Communications Manager
E: investor@pharming.com
FTI Consulting, London,
UK
Victoria Foster
Mitchell/Alex Shaw/Amy
Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens
T: +31 6 53 81 64 27 E: pharming@lifespring.nl
Logo:
https://mma.prnewswire.com/media/2003587/Pharming_Group_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/notice-of-first-quarter-2023-results-301801417.html